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CLINICAL STUDY 
Abstract 
Objective 
To study the influence of glycemic control on bone minerals and biochemical markers of bone 
metabolism in patients with type 2 diabetes mellitus.  
Methods 
A Case-control study was conducted at Uhod Hospital, KSA from October 2003 to August 
2004 to study 60 premenopausal, multipareous female patients with type 2 diabetes mellitus 
for >5 years, under oral anti-diabetics, with no diabetic complications. They were divided 
according to their glycemic control into:  controlled group (n=22) and poorly controlled 
group (n=38) and were compared to 30 age matched healthy women. Osteocalcin (OC), 
urinary deoxypyridinoline (Dpd), Parathyroid hormone (PTH) were measured by 
chemiluminescent enzyme immunometric assay and 25 hydroxy vitamin D (25 OH-D) was 
measured by high performance liquid chromatography. 
Results 
In both diabetic groups, there were higher ALP (177± 39.88 & 287 ± 41.4 mg/dl) and PTH (49 
±9.87 & 56.25± 12.3 Pg/ml) than in controls (144 ± 22.54 mg/dl, 26.9± 5.60 Pg/ml respectively 
), but lower serum calcium (8.87± 0.3 & 8.79 ±0.7 mg/dl), and 25 OH-D (50.9±12.6, 45.4±18.9 
Pg/l) and osteocalcin (4.09 ± 1.48 & 1.89 ± 0.24 ng/ml) than controls (9.96± 1.9l , 57.9±13.6 
Pg/l, 6.5±1.5 ng/ml respectively), Urinary calcium and urinary Dpd were higher (270.66±41.7 
& 300.56 ± 55.67 mg/d & 10.8 ± 4.6, 12.06±5.12 nM/mM creatinine) than in controls (244.23 
±51.5 mg/d, 6.2 ±0.8 nM/mM creatinine). Glycemic indices (FBG, HbA1C) showed significant 
positive correlation with ALP (r=0.290 & 0.294), urinary calcium (r=0.340 & 0.260) and Dpd 
(r=0.468 & 0.228). 
Conclusion 
 Our data give evidence of altered bone metabolic markers in both controlled and 
uncontrolled female patients with type 2 diabetes mellitus with more significant alterations in 
the uncontrolled group. This could reflect the strong impact of glycemic control on diabetic 
bone turnover. 
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Introduction  
 
keletal involvement in patients with 
diabetes mellitus was initially described 
over 50 years ago1, 2. The association 
between diabetes and osteoporosis has been 
extensively investigated, as both diseases 
are very common and of great 
socioeconomic relevance. However, despite 
numerous publications addressing this 
problem, many questions remain 
unanswered3. Several mechanisms may 
contribute to skeletal damage, including the 
increased urinary excretion coupled with 
the lower intestinal absorption of calcium4, 
the inappropriate homeostatic response in 
terms of parathyroid hormone secretion, 
and also the complex alteration of vitamin D 
regulation5. Decreased or increased insulin, 
impaired insulin action and IGF-1 
concentrations6, sustained hyperglycemic 
state, and the effects of the accumulation of 
glycation end products on the bone tissue6 
could also play a role. Moreover, 
considerable disagreement still persists 
upon the possible influences on bone tissue 
exerted by gender7, metabolic control of 
diabetes8, and disease duration9. 
A possible role of the fat tissue, which is 
augmented in type 2 diabetes, apart from 
mechanical stress, the increased production 
of oestrogen protects against osteopenia in 
type 2 diabetic patients10, It is also 
noteworthy that leptin, a peptide produced 
by adipocyte, has recently emerged as a 
potential candidate responsible for 
protective effects of fat on the bone tissue11. 
Also, adiponectin may regulate fat cell 
formation in bone marrow, and fat marrow 
is increased with ageing and in patients with 
osteoporosis12. 
It has been hypothesized that 
microangiopathy13, as well as 
macroangiopathy14 might also directly 
influence skeletal tissue, according to the 
most recent beliefs on regulation of bone 
metabolism15. 
As far as bone mass is concerned, in adult 
patients with type 1 diabetes a moderately 
reduced bone mineral density has been 
shown in both axial and appendicular 
skeleton. On the contrary, patients with type 
2 diabetes seem to have higher bone mineral 
density in respect to healthy control 
subjects, especially when overweight 
women are considered16. No clear 
relationship between bone mass 
measurements and biochemical parameters 
of mineral metabolism has been shown in 
the different types of diabetes17. 
Cohort studies recently carried out on large 
samples indicate that diabetic patients (with 
both type 1 and type 2 disease) have a 
higher risk for fracture, in particular for hip 
fracture, the most dangerous osteoporotic 
complication3. This seems to be dependent 
both on qualitative and quantitative 
alterations of the bone, as well as on extra-
skeletal factors due to the neuropathic and 
other microangiopathic complications of the 
disease13 - 15. 
According to these premises, the 
indiscriminate inclusion in the investigated 
samples of diabetic patients with different 
pathogenesis, or assuming different 
therapies, or with various disease duration, 
could have provided as many confounding 
factors in both clinical and epidemiological 
investigations. The different design of the 
studies that investigated populations of 
varying ages and genders also contribute to 
the conflicting results. Finally, the 
assessment of bone mass with various 
techniques (measuring either more cortical 
or more trabecular bone) could have been 
detrimental to a unified conclusion3. 
Therefore, The present study was 
undertaken to clarify the influence of 
glycemic control on bone turnover using 
biochemical bone markers in type 2 diabetes 
female patients. 
Materials and Methods 
 
This case- control study had included 60 
patients and 30 health subjects selected from 
Out-patient Department of Uhod Hospital, 
Madinah, KSA, from October 2003 till 
August 2004. All participants gave verbal 
consent to participate in this study. 
Inclusion criteria were patients who were 
overweight, with type 2 diabetes for more 
S 
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than 5 years duration with BMI >25 and 
were under oral antidiabetic therapy 
metformin, or sulfonylurea agent or both. 
All were premenopausal females with 
history of multiple pregnancies and regular 
menstrual cycles. They had normal thyroid, 
kidney, and liver function tests, normal 
serum albumin and complete blood count. 
They were divided into good controlled and 
poorly controlled groups according to the 
criteria of ADA (fasting blood glucose 90–
130 mg/dl and A1C <7%).  
Exclusion criteria were diabetic patients 
under insulin therapy, with microvascualr 
or macrovascualr diabetic complications, 
patients with other known risk factors for 
osteoporosis other than diabetes, cigarette 
smokers, patients with dietary lack of 
calcium, patients on drugs that could affect 
bone metabolism or calcium metabolism 
during the previous 6 months, including 
calcium, sex steroids, corticosteroids, 
vitamin D metabolites, calcitonin, warfarin, 
vitamin K, thiazides, anticonvulsants; 
thyroxin and bisphosphonate. Patient who 
was found to have vitamin D deficiency 
(plasma level <14 Pg/L) were also excluded 
from the study. 
Inclusion criteria for control group were age 
and weight matched healthy premenopausal 
females with history of multiple pregnancies 
and regular menstrual cycles, with history 
of balanced diet and without history of any 
known risk factor for osteoporosis.  
After through history and clinical 
examination, height and weight were 
measured with the patient standing in light 
clothes and without shoes. BMI was 
calculated as body weight divided by height 
squared (kilograms per meter squared).  
Ten ml fasting venous blood sample were 
withdrawn from each participant, 2 ml was 
taken on EDTA as anticoagulant for 
determination of glycohaemoglobin 
(HbA1c). Two ml blood were put on 
heparin, placed immediately on ice and 
plasma was separated and centrifuged in a 
cooling centrifuge, plasma was separated 
and stored at 20°C for estimation of 
osteocalcin and vitamin D, another 2 ml 
blood were placed on ice, serum was 
separated and stored at 20°C for estimation 
of parathyroid hormone (PTH). Another 2 
ml blood were put on floride, and plasma 
was separated for estimation of fasting 
blood glucose level. The remaining 2 ml of 
blood was centrifuged and serum was 
separated for estimation of bone minerals 
(Ca, Ph) and kidney function test (urea and 
creatinine). On the same day of blood 
sampling, the last 24 hours urine samples 
were collected for measurement of urinary 
calcium at 8.00 AM and the morning 1st or 
2nd void urine sample was stored in a dark 
container for estimation of 
deoxypyridinoline (DPd).  
The FBG was measured using an enzymatic 
oxidation in the presence of glucose oxidase 
(The Kits provided by Randox GOD/PAP, 
Diamond Road, Crumlin, Co Antrim, 
United Kingdom). The HbA1c 
determination was based on turbidimetric 
inhibition immunoassay (TINIA) for 
hemolyzed whole blood samples (The kits 
was supplied by BioSource International, 
Inc. 542 Flynn Road, Camarillo, California 
93012 USA). Serum Ca, Ph, alkaline 
phosphatase (ALP), urea and creatinine 
were measured by Boechringer Mannheim 
911 Hitachi automated analysis.  
The serum osteocalcin level is measured 
with a commercially available N-MID 
Osteocalcin Electrochemiluminescence 
Immunoassay kit (Roche Diagnostics 
GmbH, Mannheim, Germany) [18]. DPD 
and PTH analysis were determined by solid-
phase two site chemiluminescent enzyme 
immunometric assay, performed on 
immulite auto analyses using kit supplied 
by DPC (Diagnostic Product Corporation, 
5700 west 96th street, USA). Plasma 25, 
hydroxyl Vitamin D3 (25 OH-D) was 
measured according to Chromosystem 
reagent kit for high performance liquid 
chromatography (HPLC). 
 
Statistical Methods 
 
Statistical evaluation of all data was done on 
IBM-PC microprocessor computer using 
SPSS software for windows (Statistical 
Package for Social Sciences version 11, 
Entessar Sultan et al
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USA) for data management and analysis 
and the Microsoft power point for charts. 
Quantitative data were presented as mean ± 
SD. For the comparison of the three groups' 
means, one way analysis of variance 
(ANOVA) was used followed by Students' 
Newman Keuls test to detect significant 
difference. All tests were two tailed and 
considered significant when p<0.05. The 
coefficients of correlation between levels of 
glucose, minerals, and bone markers were 
calculated according to Pearson’s method.  
 
Results 
 
Analysis of the age (years) and body mass 
index BMI (Kg/m2) in the different studied 
groups shows that they were age matched 
(46.1 ± 6.45, 49 ± 5.14 & 47.8±8. 79 years for 
controlled, uncontrolled diabetics and 
control group respectively, p<0.05). The 
mean duration of diabetes did not differ 
between the 2 diabetic groups (6.6±0.4 & 
7.3± 1.1 years, p<0.05). All were overweight 
(29.38±6.00, 28.86±6.00 & 27.59±5.12 BMI 
respectively, p<0.05; Figure 1). 
The fasting blood sugar levels of both 
diabetic groups (98.1 ± 73.57 & 239.64± 97.78 
mg/dl) were significantly higher than in 
controls (83 ± 7.6 mg/dl, p>0.05 & <0.01 
respectively) (figure 2). Similarly, HbA1c 
levels of both diabetic groups (5.9±0.8 and 
9.05±3.29) were significantly higher than in 
controls (5.1±0.35, p>0.05 & p<0.01 
respectively; Figure 3).  
Serum calcium levels of both diabetic 
groups (8.87± 0.3 & 8.79 ±0.7 mg/dl) were 
found to be significantly lower compared 
with the control group, especially the 
uncontrolled group (9.96± 1.9 mg/dl, p<0.05 
& P<0.001 respectively). However there was 
no difference between all studied groups 
concerning serum phosphorous levels (3.98 
± 0.92, 2.78 ± 0.63 & 4.3 ± 0.39 mg/dl 
respectively, p>0.05; Figure 4).  
ALP levels of both diabetic groups (177± 
39.88 & 287 ± 41.4 mg/dl) were significantly 
higher than in control group, especially the 
uncontrolled group (144 ± 22.54 mg/dl, 
p<0.05 & p<0.001 respectively; Figure 5). 
PTH level was significantly higher in both 
diabetic groups (49 ±9.87 & 56.25± 12.3) 
compared with control group (26.9± 5.60, 
p<0.01). vitamin D levels in both diabetic 
groups (50.9±12.6, 45.4±18.9 ) were 
significantly lower than the controls 
(57.9±13.6, p<0.05; Figure 6).  
A lower level of osteocalcin was found in 
both diabetic groups especially the 
uncontrolled one (4.09 ± 1.48 & 1.89 ± 0.24 
ng/ml) compared with control group 
(6.5±1.5 ng/ml p>0.05 and <0.01 
respectively; Figure 7).  
Both diabetic groups showed increased 
levels of urinary calcium (270.66±41.7  and 
300.56. ±55.67 mg) significantly than the 
control group (244.23 ±51.5 mg), especially 
the uncontrolled one (p<0.05 & p<0.001 
respectively; Figure 5). 
Similar results were detected for urinary 
Dpd (10.8 ± 4.6, 12.06±5.12, 6.2 ±0.8 nM/mM 
creatinine, P <0.05 & p<0.001 respectively); 
Figure 7). 
 PTH level in all diabetic patients 
was found to correlate positively with ALP 
level (r= 0.54, P<0.01) and negatively with 
serum calcium (r =-0.65, P<0.01). Glycemic 
indices (FBG, HbA1C) showed significant 
positive correlation with alkaline 
phosphatase (0.290 & 0.294 respectively, 
p<0.01 for both), 24 hours urinary calcium (r 
= 0.340, P<0.01&0.260, p<0.5 respectively) 
and Dpd (0.468, p<0.01, 0.228, p<0.05 
respectively). Dpd correlated also with 
urinary calcium (0.278, p<0.5). Serum 25 
OH- vitamin D levels were negatively 
correlated to PTH levels (r=-0.290, P < 0.01). 
OC and types of treatment (i.e. metformin 
with or without sulphonylurea) did not 
show correlation with any of the studied 
parameters. 
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Figure 1: Analysis of the age (years) and body mass index BMI (Kg/m2) in the different studied groups; 
normal control, good controlled type 2 Diabetes mellitus and poorly controlled type 2 Diabetes mellitus 
patients using Students` Newman Keuls multiple comparison test at level of significance p<0.05. All data 
were non-significant in comparison to normal control group.  
Data were expressed as mean ± S.D. NC=normal control, n= 30; Poorly C DM= poorly controlled type 2 
Diabetes mellitus, n= 38; Good C DM= good controlled type 2 Diabetes mellitus, n= 22. 
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Figure 2: Fasting blood glucose (mg%) in the different studied groups; normal control, good controlled 
type 2 Diabetes mellitus and poorly controlled type 2 Diabetes mellitus patients using Students` Newman 
Keuls multiple comparison test at level of significance p<0.01.  
Data were expressed as mean ± S.D. *Significant change difference compared with normal control group at 
p<0.05. NC=normal control, n= 30; Poorly C DM= poorly controlled type 2 Diabetes mellitus, n= 38; 
Good C DM= good controlled type 2 Diabetes mellitus, n= 22.
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Figure 3: Plasma glycohaemoglobin (%) in the different studied groups; normal control, good controlled 
type 2 Diabetes mellitus and poorly controlled type 2 Diabetes mellitus patients using Students` Newman 
Keuls multiple comparison test at level of significance p<0.01.  
Data were expressed as mean ± S.D. *Significant change difference compared with normal control group at 
p<0.05. NC=normal control, n= 30; Poorly C DM= poorly controlled type 2 Diabetes mellitus, n= 38; 
Good C DM= good controlled type 2 Diabetes mellitus, n= 22. 
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Figure 4: Serum calcium (mg%0 and serum phosphorous (mg%) in the different studied groups; normal 
control, good controlled type 2 Diabetes mellitus and poorly controlled type 2 Diabetes mellitus patients 
using Students` Newman Keuls multiple comparison test at level of significance p<0.01.  
Data were expressed as mean ±S.D. *Significant change difference compared with normal control group at 
p<0.05. NC=normal control, n= 30; Poorly C DM= poorly controlled type 2 Diabetes mellitus, n= 38; 
Good C DM= good controlled type 2 Diabetes mellitus, n= 22. 
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Figure 5: Alkaline phosphatase (mg%) and 24 hours urinary calcium (mg) in the different studied groups; 
normal control, good controlled type 2 Diabetes mellitus and poorly controlled type 2 Diabetes mellitus 
patients using Students` Newman Keuls multiple comparison test at level of significance p<0.01.  
Data were expressed as mean ± S.D. *Significant change difference compared with normal control group at 
p<0.05. NC=normal control, n= 30; Poorly C DM= poorly controlled type 2 Diabetes mellitus, n= 38; 
Good C DM= good controlled type 2 Diabetes mellitus, n= 22. 
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Figure 6: Vitamin D (  JPODQGSDUDWK\
control, good controlled type 2 Diabetes mellitus and poorly controlled type 2 Diabetes mellitus patients 
using Students` Newman Keuls multiple comparison test at level of significance p<0.01.  
Data were expressed as mean ± S.D. *Significant change difference compared with normal control group at 
p<0.05. NC=normal control, n= 30; Poorly C DM= poorly controlled type 2 Diabetes mellitus, n= 38; 
Good C DM= good controlled type 2 Diabetes mellitus, n= 22.
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Figure 7: Osteocalcin (ng/ml) and deoxypyridinoline (nM/mM creatinine) in the different studied groups; 
normal control, good controlled type 2 Diabetes mellitus and poorly controlled type 2 Diabetes mellitus 
patients using Students` Newman Keuls multiple comparison test at level of significance p<0.01.  
Data were expressed as mean ± S.D. *Significant change difference compared with normal control group at 
p<0.05. NC=normal control, n= 30; Poorly C DM= poorly controlled type 2 Diabetes mellitus, n= 38; 
Good C DM= good controlled type 2 Diabetes mellitus, n= 22. 
 
 
Discussion 
 
From results, it is plausible to assume that 
both the resorption and formation of bone 
are altered in premenopausal type 2 
diabetes and these alterations are directly 
influenced by the degree of diabetic control.  
Both diabetic groups were associated with 
an increase in Dpd, a marker of bone 
resorption and a decrease in OC, a marker of 
bone formation. Also, Dpd was positively 
correlated with glycemic indices. The 
decrease in OC among diabetic patients has 
been previously reported9, 20, 21 and is 
interpreted to represent a reduction in bone 
formation. In contrast, other researchers 
found that bone ALP, another bone 
formation marker, tends to be elevated in 
diabetic patients22, 23. Bone alkaline 
phosphatase and osteocalcin are both 
synthesized by osteoblast and are currently 
considered the most sensitive markers to 
assess bone formation23. In this work, total 
alkaline phosphatase was done and not the 
specific bone one and it was found to be 
higher   in    all    diabetic   patients    versus 
 
 
 
 
control group (Figure 5) with positive 
correlation with glycemic indices.  
The detected elevation in ALP level could be 
explained by the prolonged exposure to 
PTH which eventually increases osteoblastic 
activity. While reduction of the osteocalcin 
level could result from inhibition of 
osteoblast function due to impaired insulin 
secretion and increase in insulin resistance 
leading to hyperglycemia24.  
Diabetes-associated hyperglycemia may 
modulate osteoblast gene expression, 
function and bone formation25. Sustained 
hyperglycemia alone causes suppression of 
osteoblast proliferation and its response to 
parathyroid hormone and 1 alpha, 25-
dihydroxyvitamin D. Hyporesponse of 
osteoblast to 1 alpha, 25-dihydroxyvitamin 
D, was also confirmed in diabetic patients as 
reflected by a reduction in an incremental 
response of serum OC during 1, 25-
dihydroxyvitamin D administration26. It is 
not known whether decreased OC is a 
predictive factor for fractures in diabetes, 
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but its levels have been found to return 
toward the normal range after glycemic 
control. Since OC is known to be 
glycosylated, it is also possible that the 
measurement would be affected by high 
glucose conditions9. Therefore, in poorly 
controlled diabetics, OC may not properly 
reflect bone formation. Such a possibility is 
corroborated by our observation that OC 
was not correlated with any other metabolic 
bone markers or with indices of glycemic 
control. 
Elevated Dpd in diabetics could be 
explained by the fact that bone blood flow is 
increased in the distal limb of diabetic 
patients, which is believed to increase 
osteoclastic activity27. Also Endre and 
Robert28 reported acute reduction in 
collagen synthesis and increase osteoclastic 
bone resorption in diabetic patients with a 
net increase in minerals released from bone 
into extracellular fluid. Elevated urinary 
Dpd in diabetics, especially those with poor 
metabolic control in whom the rate of bone 
resorption is increased, exposes growing 
diabetic patients to the risk of bone loss. In 
harmony with our results were those of 
others7, 21. On the other hand, Gerdhem and 
his co-workers17, reported reduction in 
urinary Dpd level on comparing type 2 
diabetes patients to control group, in spite of 
the reduction in osteocalcin level in those 
patients. This was attributed to the fat that 
only the bone formation phase was affected 
in diabetics, while the resorption phase 
remained unaltered. 
The mechanism whereby bone turnover is 
affected by glycemic control status is not 
clear at the moment. Results show a 
significant increase in urinary calcium in 
both diabetic groups more significant in the 
uncontrolled group. Also, urinary Ca 
excretion was correlated with both the 
glycemic indices and bone resorption 
marker Dpd. Increased urinary calcium, 
phosphate, and magnesium have been 
found in diabetic patients with poor 
metabolic control, whose renal excretion 
rates correlated positively with the degree of 
hyperglycemia and glycosuria5. 
Hypercalciuria has been traced back both to 
the osmotic diuresis promoted by glycosuria 
and to renal hemodynamic changes induced 
by prostaglandin excess18. The increased 
renal leak appears to be associated with 
lower duodenal calcium absorption. It has 
been speculated that hyperphagia, although 
it determines higher calcium intake, may 
limit the efficacy of active calcium transport, 
inducing an overall decrease in intestinal 
absorption4. The reduced concentrations of 
the binding protein calbindin D-9K in the 
duodenal mucosa29 could contribute to 
calcium malabsorption.  
In type 2 diabetes patients, the mean serum 
calcium level was significantly lower than 
the control group, mean serum phosphorus 
level was also lower than the control group, 
yet the difference was statistically 
insignificant (Figure 4). These results agreed 
with others30, 31. The reduction in serum 
calcium level is most probably due to 
several factors: reduction in insulin level 
which impairs bone formation due to its 
stimulatory action on osteoblast 
proliferation, and impairment of calcium 
homeostasis, also hyperglycemia increase 
calcium and phosphorus excretion in urine 
which is proportional to the degree of 
glucosuria1. 
It is tempting to speculate from these data 
that renal hypercalciuria by osmotic diuresis 
caused stimulation of bone resorption 
caused by secondary hyperparathyroidism. 
PTH level was found to be higher in both 
diabetic groups than in control group 
especially in uncontrolled patients (figure 6). 
Other workers are in agreement with our 
results32 - 34. Physiologically, the reduced 
intestinal absorption, together with the 
increased urinary calcium excretion, should 
induce a compensatory increase of 
parathyroid hormone (PTH) secretion. Also, 
the reduction of serum-ionized calcium due 
to higher concentration of the complexed 
ion35 should promote PTH secretion in these 
patients. On the other hand, some other 
studies17, 36 reported no change in values of 
PTH in diabetics compared to non-diabetics. 
Other researchers reported a lower PTH 
level in type 2 diabetes patient than the 
control group31, 37, 38 and they explained their 
findings by the inverse correlation noted 
between blood glucose and PTH suggesting
Entessar Sultan et al
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that hyperglycemia per se may have an 
inhibitory action on the synthesis and 
secretion of PTH. This is consistent with 
experimental studies in bovine parathyroid 
cell culture. This state of 
hypoparathyroidism has been reported to be 
correlated with the duration of diabetes and 
the degree of hyperglycemia39.  
The discrepant data of PTH are partly 
related to the different assays employed for 
its measurement, which can detect either 
active or inactive fragments of the hormone 
molecule. However, overall, parathyroid 
hormone secretion seems to be lower than 
expected for the homeostatic needs40. This 
state of functional hypoparathyroidism  
has also been confirmed by dynamic 
challenge studies, such as during citrate-
induced hypocalcemia40, or 
hyperinsulinemic hypoglycemia41, or 
following an oral glucose tolerance test42. 
Functional hypoparathyroidism has been 
related to magnesium deficiency43 and has 
been considered responsible for the low 
bone turnover44. 
In agreement with other studies17, 44 Vitamin 
D was found to be lower in both diabetic 
groups than in control group (more 
significant in uncontrolled patients; Figure 
6). Several studies have investigated the 
possible role of vitamin D in the 
pathogenesis of skeletal involvement. It has 
been shown that the balance among the 
major vitamin D metabolites is altered. For 
instance, 24, 25-dihydroxyvitamin D levels 
are markedly reduced and not correlated 
with those of 25-hydroxyvitamin D, in 
contrast to that in normal subjects45. Others 
described variations of vitamin D 
metabolism included the decreased 
synthesis of vitamin D-binding protein by 
the liver, decreased renal 1 -hydroxylase 
activity, and reduced vitamin D-receptor 
concentrations. The latter could induce 
peripheral vitamin D resistance46. Calcitriol 
receptors have been demonstrated on islet 
cells of the pancreas, and vitamin D 
deficiency may alter insulin secretion. This 
could explain reports of a significant inverse 
correlation between glucose levels after oral 
glucose load and serum 25-hydroxyvitamin 
D concentrations in elderly men47. This 
finding is relevant, since circulating 25-
hydroxyvitamin D levels are considered the 
best index of nutritional vitamin D status48. 
On the other hand, normal 25-
hydroxyvitamin D levels were detected in 
some studies in diabetic patients49. Different 
results on vitamin D status may be due to 
several factors such as the assay employed, 
the cutoff value utilized for defining 
hypovitaminosis, and the physiological 
seasonal variations of vitamin synthesis49. 
The fact that the glycemic indices correlates 
with the bone resorption marker DPD, 
alkaline phosphatase and urinary calcium 
suggests that the better glycemic control 
would be associated with the lower bone 
loss. However, the presence of altered bone 
turnover in good controlled patients needs 
to be explained. Bone turnover is regulated 
by many local cytokines, cell-cell, and cell-
matrix interactions as well as systemic 
hormones, and hyperglycemia may affect 
any of these local microenvironments that 
regulate bone turnover. McCarthy et al.6
reported that advanced glycosylation 
endproducts (AGEs) stimulate production 
of interleukin-6, a bone resorbing cytokine, 
in human and mouse osteoblast-like cells in 
culture. Because the formation of AGEs is 
considered irreversible, this mechanism 
could partially explain the altered bone 
turnover in the presence of good glycemic 
control. Further studies are needed to clarify 
these issues.  
Conclusion 
Our data give evidence of altered bone 
minerals, vitamin D metabolism and 
increase bone turnover in patients with 
Type 2 diabetes mellitus. These alterations 
were already present in patients with good 
metabolic control. On the other hand, the 
greatest alteration was observed in poorly 
controlled patients. Therefore, we can 
conclude that loss of skeletal tissue in 
diabetes could reflect the underlying disease 
with strong influence of hyperglycemia. 
Therefore, the regimens having stimulatory 
effect on bone turnover, such as intermittent 
PTH therapy and vitamin D, are
Altered bone metabolic markers and diabetes mellitus 
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 recommended to treat diabetic osteopenia, 
besides improvement of diabetic control 
state. 
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